Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released positive topline data from its phase 2a clinical trial of AP-325. The trial ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...

which is nearing initiation of Phase 2 clinical trial in patients with moderate-to-severe rheumatoid arthritis, and a Phase 2a clinical trial for an additional autoimmune indication. Uvax Bio ...

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response in the first patient treated with Bria-OTS, the company's novel ...

LLC ("Zina") to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease. Under the terms of the agreement, Zina will provide comprehensive services related to ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for ...

Immuneering plans to expand phase 2a trials with new combination arms, targeting BRAF-mutant melanoma and non-small cell lung cancer. A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...